New drug combo aims to extend life in tough pancreatic cancer

NCT ID NCT06953999

Recruiting now Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Mar 04, 2026 · Last updated May 14, 2026 · Updated 12 times

Summary

This study tests whether adding the drugs ivonescimab and AK117 to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 adults aged 18-75 who have not had prior treatment for their advanced cancer will be randomly assigned to receive either the new drug combination or a placebo plus chemo. The main goal is to see if the new treatment improves overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 20032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PANCREATIC CANCER